Summary of notifiable diseases, United States 1998

Morbidity and Mortality Weekly Report

Volumn 47, Issue 53, 1999, Pages 1-116

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2042483758     PISSN: 01492195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Roush S, Birkhead G, Koo D, Cobb A, Fleming D. Mandatory reporting of diseases and conditions by health care professionals and laboratories. JAMA 1999;282:164-70.
2. CDC. Reporting race and ethnicity data - National Electronic Telecommunications System for Surveillance, 1994-1997. MMWR 1999;48:305-12.
3. Niskar AS, Koo D. Differences in notifiable infectious disease morbidity among adult women - United States, 1992-1994. J Womens Health 1998,7:451-8.
4. CDC. Case definitions for infectious conditions under public health surveillance. MMWR 1997;46(No. RR-10). Also available on the Internet at 〈http://www.cdc.gov/epo/dphsi/casedef/cover97.htm〉. Accessed July 23, 1999.
5. CDC. Sexually transmitted disease surveillance 1997. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1998.
6. CDC. Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: US Department of Health and Human Services, CDC, 1997. Also available on the Internet at the following site: 〈http://www.cdc.gov/nip/ publications/manual/vpd.htm〉. Accessed July 23, 1999.
7. CDC. Demographic differences in notifiable infectious disease morbidity -United States, 1992-1994. MMWR 1997;46:637-41.
8. CDC. Notifiable disease surveillance and notifiable disease statistics - United States, June 1946 and June 1996. MMWR 1996;45:530-7.
9. Koo D, Wetterhall S. History and current status of the National Notifiable Diseases Surveillance System. Journal of Public Health Management and Practice 1996;2:4-10.
10. CDC. Ten leading nationally notifiable infectious diseases - United States, 1995. MMWR 1996;45:883-4.
11. Benenson AS. Control of communicable diseases in man. 16th ed. Washington, DC: American Public Health Association, 1995.
12. Martin SM, Bean NH. Data management issues for emerging diseases and new tools for managing surveillance and laboratory data. Emerg Infect Dis J 1995;1:124-8.
13. CDC. Manual of procedures for the reporting of nationally notifiable diseases to CDC. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1995.
14. Teutsch SM, Churchill RE, eds. Principles and practice of public health surveillance. New York, NY: Oxford University Press, 1994.
15. Thacker SB, Stroup DR Future directions for comprehensive public health surveillance and health information systems in the United States. Am J Epidemiol 1994;140:383-97.
16. CDC. Use of race and ethnicity in public health surveillance. MMWR 1993;42(No. RR-10).
17. CDC. Mandatory reporting of infectious diseases by clinicians, and mandatory reporting of occupational diseases by clinicians. MMWR 1990;39(No. RR-9).
18. Thacker SB, Choi K, Brachman PS. The surveillance of infectious diseases. JAMA 1983;249:1181-5.
19. CDC. Characteristics of persons living with AIDS at the end of 1997. HIV/AIDS Surveillance Supplemental Report 1999;5(No. 1).
20. CDC. Success in implementing PHS guidelines to reduce perinatal transmission of HIV - Louisiana, Michigan, New Jersey, and South Carolina, 1993, 1995, and 1996 [published errata appear in MMWR 1998;47:718]. MMWR 1998;47:688-91.
21. CDC. Diagnosis and reporting of HIV and AIDS in states with integrated HIV and AIDS surveillance - United States, January 1994-June 1997. MMWR 1998;47:309-14.
22. CDC. HIV/AIDS Surveillance Report 1998;10(No. 2).
23. Angulo FJ, Getz J, Taylor JP, et al. A large outbreak of botulism: the hazardous baked potato. J Infect Dis 1998;178:172-7.
24. CDC. Botulism in the United States, 1899-1996. Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta, GA: US Department of Health and Human Services, CDC, 1998. Also available at 〈http://www.cdc. gov/ncidod/dbmd/diseaseinfo/botulism.pdf〉. Accessed July 23, 1999.
25. Shapiro RL, Hatheway C, Becher J, Swerdlow D. Botulism surveillance and emergence response: a public health strategy for a global challenge. JAMA 1997;278:433-5.
26. Mertz KJ, Weiss JB, Webb RM, et al. An investigation of genital ulcers in Jackson, Mississippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. J Infect Dis 1998;178:1060-6.
27. Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998;178:1795-8.
28. DiCarlo RP, Armentor BS, Martin DH. Chancroid epidemiology in New Orleans men. J Infect Dis 1995;172:446-52.
29. CDC. Chancroid in the United States, 1981-1990: evidence for underreporting of cases. In: CDC surveillance summaries, May 29, 1992. MMWR 1992;41(No. SS-3):57-61.
30. CDC. Sexually transmitted disease surveillance 1997 supplement. Chlamydia prevalence monitoring project annual report-1997. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1998.
31. Gaydos CA, Howell MR, Pare B, et al. Chlamydia trachomatis infections in female military recruits. N Engl J Med 1998;339:739-44.
32. Mertz KJ, McQuillan GM, Levine WC, et al. A pilot study of the prevalence of chlamydial infection in a national household survey. SexTransm Dis 1998;25:225-8.
33. CDC. Chlamydia trachomatis genital infections - United States, 1995. MMWR 1997;46:193-8.
34. Ackers ML, Quick RE, Drasbeck CJ, Hutwagner L, Tauxe RV. Are there national risk factors for epidemic cholera? The correlation between socioeconomic and demographic indices and cholera incidence in Latin America. Int J Epidemiol 1998;27:330-4.
35. Mahon BE, Mintz ED, Greene KD, Wells JG, Tauxe RV. Reported cholera in the United States, 1992-1994: a reflection of global changes in cholera epidemiology. JAMA 1996;276:307-12.
36. Wachsmuth IK, Blake PA, OlsvikO, eds. Vibrio choleras and cholera: molecular to global perspectives. Washington, DC: American Society for Microbiology, 1994.
37. Blake PA. Epidemiology of cholera in the Americas. Gastroenterol Clin North Am 1993;22:639-60.
38. World Health Organization. Guidelines for cholera control. Geneva: World Health Organization, 1993.
39. Kramer MH, Herwaldt BL, Craun GF, Calderon RL, Juranek DD. Surveillance for waterborne-disease outbreaks - United States, 1993-1994. In: CDC surveillance summaries, April 12, 1996. MMWR 1996;45(No. SS-1).
40. Juranek DD. Cryptosporidiosis: sources of infection and guidelines for prevention. Clin Infect Dis 1995;21(suppl 1):S57-S61. Also available on the Internet at the following site: 〈http://www.cdc.gov/ncidod/diseases/crypto/ sources.htm〉. Accessed July 23,1999.
41. CDC. Assessing the public health threat associated with waterborne Cryptosporidiosis: report of a workshop. MMWR 1995;44(No. RR-6). Also available on the Internet at the following site: 〈http://www.ftp.cdc.gov/pub/ Publications/mmwr/rr/rr4406.pdf〉. Accessed July 23, 1999.
42. Herwaldt BL, Beach MJ. The return of Cyclospora in 1997: another outbreak of cyclosporiasis in North America associated with imported raspberries. Cyclospora Working Group. Ann Intern Med 1999;130:210-20.
43. CDC. Outbreak of cyclosporiasis - Ontario, Canada, May 1998. MMWR 1998;47:806-9.
44. Herwaldt BL, Ackers ML, Cyclospora Working Group. An outbreak in 1996 of cyclosporiasis associated with imported raspberries. N Engl J Med 1997;336:1548-56.
45. Rigau-Pérez JG, Millard PS, Walker DR, Deseda CC, Casta-Velez A. A deviation bar chart for detecting dengue outbreaks in Puerto Rico. Am J Public Health 1999;89:374-8.
46. CDC. Dengue outbreak associated with multiple serotypes - Puerto Rico, 1998. MMWR 1998;47:952-6.
47. Rawlings JA, Hendricks KA, Burgess CR, et al. Dengue surveillance in Texas, 1995. Am J Trop Med Hyg 1998;59:95-9.
48. Organizatión Panamericana de la Salud. Situación de las enfermedades infecciosas de mayor riesgo epidemiológico en el período post-Mitch, países de Centroamérica, 1998 [Segundo informe]. Washington, DC: Organization Panamericana de la Salud, Programa de Enfermedades Transmisibles, División de Preventión y Control de Enfermedades, 1998;OPS/HCP/HCT/134/98:5-8.
49. Bisgard K, Hardy I, PopovicT, et al. Respiratory diphtheria in the United States, 1980-1995. Am J Public Health 1998;88:787-91
50. Vitek CR, Wharton M. Diphtheria in the former Soviet Union: reemergence of a pandemic disease [Review]. Emerg Infect Dis 1998;4:539-50.
51. Jones IF, Craig AS, Nasci RS, et al. Newly recognized focus of La Crosse encephalitis in Tennessee. Clin Infect Dis 1999;28:93-7.
52. CDC. Arboviral infections of the central nervous system - United States, 1996-1997. MMWR 1998;47:517-22.
53. Szumlas DE, Apperson CS, Hartig PC, Francy DB, Karabatsos N. Seroepidemiology of La Crosse virus infection in humans in western North Carolina. Am J Trop Med Hyg 1996;54:332-7.
54. Marfin AA, Bleed DM, Lofgren JP, et al. Epidemiologic aspects of a St. Louis encephalitis epidemic in Jefferson County, Arkansas, 1991. Am J Trop Med Hyg 1993;49:30-7.
55. CDC. PulseNet. The National Molecular Subtyping Network for Foodborne Disease Surveillance. Available on the Internet at 〈http://www.cdc.gov/ ncidod/dbmd/pulsenet/pulsenet.htm〉. Accessed July 23, 1999.
56. Bender JB, Hedberg CW, Besser JM, Boxrud DJ, MacDonald KL, Osterholm MT. Surveillance for Escherichia coli O157:H7 infections in Minnesota by molecular subtyping. N Engl J Med 1997;337:388-94.
57. Mahon BE, Griffin PM, Mead PS, Tauxe RV. Hemolytic uremic syndrome surveillance to monitor trends in infection with Escherichia coli O157:H7 and other Shiga toxin-producing E. coli. Emerg Infect Dis 1997;3:409-12.
58. Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, Griffin PM. Escherichia coli 0157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997;126:505-13.
59. CDC. Increases in unsafe sex and rectal gonorrhea among men who have sex with men - San Francisco, California, 1994-1997. MMWR 1999;48:45-8.
60. CDC. Sexually transmitted diseases surveillance 1997 supplement. Gonococcal Isolate Surveillance Project (GISP) annual report - 1997. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1998.
61. Fox KK, Whittington W, Levine WC, Moran JS, Zaidi AA, Nakashima AK. Gonorrhea in the United States, 1981-1996. Demographic and geographic trends. Sex Transm Dis 1998;25:386-93.
62. Fox KK, Knapp JS, Holmes KK, et al. Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: the emergence of decreased susceptibility to the fluoroquinolones. J Infect Dis 1997;175:1396-403.
63. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzas invasive disease in the United States, 1994-1995: near disappearance of a child vaccine preventable disease. Emerg Infect Dis 1998;4:229-37.
64. CDC. Progress towards elimination of Haemophilus influenzas type b disease among infants and children - United States, 1987-1997. MMWR 1998;47:993-8.
65. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. New Engl J Med 1997;33:970-6.
66. CDC. Recommendations for the use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1993;42(No. RR-13).
67. Mills JN, Ksiazek TG, Peters CJ, Childs JE. Long-term studies of hantavirus reservoir populations in the southwestern United States: a synthesis. Emerg Infect Dis 1999;5:135-42.
68. Monroe MC, Morzunov SP, Johnson AM, et al. Genetic diversity and distribution of Peromyscus-borne hantaviruses in North America. Emerg Infect Dis 1999;5:75-86.
69. Engelthaler DM, Mosley DG, Cheek JE, et al. Climatic and environmental patterns associated with hantavirus pulmonary syndrome, Four Corners region, United States. Emerg Infect Dis 1999;5:87-94.
70. CDC. Hantavirus infection - southwestern United States: interim recommendations for risk reduction. MMWR 1993;42(No. RR-11).
71. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(No. RR-15).
72. Lemon SM, Shapiro CN. The value of immunization against hepatitis A. Infectious Agents and Disease 1994;1:38-49.
73. Shapiro CN, Coleman PJ, McQuillan GM, et al. Epidemiology of hepatitis A: seroepidemiology and risk groups in the U.S.A. Vaccine 1992;10(suppl 1):S59-S62.
74. Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS. Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998;178:954-9.
75. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
76. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(No. RR-13).
77. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19).
78. Alter MJ, Mast EE, Moyer LA, Margolis HS. Hepatitis C. Infect Dis Clin North Am 1998;12:13-26.
79. Kool JL, Carpenter JC, Fields BS. Effect of monochloraminc disinfection of municipal drinking water on risk of nosocomial Legionnaires' disease. Lancet 1999;353:272-7.
80. Jernigan DB, Hofmann J, Cetron MS, et al. Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa. Lancet 1996;347:494-9.
81. Keller DW, Hajjeh R, DeMaria A, Jr, et al. Community outbreak of Legionnaires'disease: an investigation confirming the potential for cooling towers to transmit legionella species. Clin Infect Dis 1996;22:257-61.
82. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease: risk factors for morbidity and mortality. Arch Intern Med 1994;154:2417-22.
83. CDC. Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-7).
84. Dennis DT. Epidemiology, ecology, and prevention of Lyme disease. In: Rahn DW, Evans J, eds. Lyme disease. Philadelphia, PA: American College of Physicians, 1998:7-34.
85. CDC. Lyme disease - United States, 1996. MMWR 1997:46:531-5.
86. CDC. Notice to readers: recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme disease. MMWR 1995;44:590-1.
87. Lobel HO, Kozarsky PE. Update on prevention of malaria fortravelers. JAMA 1997;278:1767-71.
88. Zucker JR. Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. Emerg Infect Dis 1996;2:37-43.
89. Zucker JR, Campbell CC. Malaria: principles of prevention and treatment. Infect Dis Clin North Am 1993;7:547-67.
90. CDC. Transmission of measles among a highly vaccinated school population - Anchorage, Alaska, 1998. MMWR 1999;47:1109-11.
91. CDC. Measles, mumps and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8).
92. CDC. Measles - United States, 1997. MMWR 1998;47:273-6.
93. Diermayer M, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999;281:1493-7.
94. Rosenstein N, Levine O, Taylor JP, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998;279:435-9.
95. CDC. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-5).
96. CDC. Laboratory-based surveillance for meningococcal disease in selected areas - United States, 1989-1991. In: CDC surveillance summaries (June 4). MMWR 1993;42(No. SS-2):21-30.
97. CDC. Mumps surveillance - United States, 1988-1993. In: CDC surveillance summaries, August 11, 1995. MMWR 1995;44(No. SS-3).
98. Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994;169:77-82.
99. Hersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991;119:187-93.
100. CDC. Recommendations of the Immunization Practices Advisory Committee on Mumps prevention. MMWR 1989;38:388-92,397-400.
101. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999;28:1230-7.
102. CDC. Notice to readers: FDA approval of a fourth acellular pertussis vaccine for use among infants and young children. MMWR 1998;47:934-6.
103. CDC. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No.RR-7).
104. Poland JD, Dennis DT. Plague. In: Evans AS, Brachman PS, eds. Bacterial infections of humans: epidemiology and control. 3rd ed. New York, NY: Plenum Publishing Corporation, 1998:545-58.
105. Gage KL. Plague. In: Hausler WJ, Jr, Sussman M, eds. Topley and Wilson's microbiology and microbial infections. Vol. 3: Bacterial infections. 9th ed. London, England: Arnold, 1998:885-903.
106. CDC. Prevention of plague. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(No. RR-14).
107. CDC. Impact of the sequential IPV/OPV schedule on vaccination coverage levels - United States, 1997. MMWR 1998;47:1017-9.
108. CDC. Paralytic poliomyelitis - United States, 1980-1994. MMWR 1997;46:79-83.
109. CDC. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-3).
110. Moroney JF, Guevara R, Iverson C, et al. Detection of chlamydiosis in a shipment of pet birds, leading to recognition of an outbreak of clinically mild psittacosis in humans. Clin Infect Dis 1998;26:1425-9.
111. Jorgensen DM. Gestational psittacosis in a Montana sheep rancher. Emerg Infect Dis 1997;3:191-4
112. CDC. Compendium of psittacosis (chlamydiosis) control, 1997. MMWR 1997;46(No. RR-13).
113. Wong KH, Skelton SK, Daugharty H. Utility of complement fixation and microimmuno-fluorescence assays for detecting serologic responses in patients with clinically diagnosed psittacosis. J Clin Microbiol 1994;32:2417-21.
114. CDC. Human rabies prevention - United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-1).
115. CDC. Compendium of animal rabies control, 1999. National Association of State and Territorial Public Health Veterinarians, Inc. MMWR 1999;48(No. RR-3).
116. Krebs JW, Smith JS, Rupprecht CE, Childs JE. Rabies surveillance in the United States during 1997. JAVMA 1998;213:1713-28.
117. Noah DL, Drenzek CL, Smith JS, et al. Epidemiology of human rabies in the United States, 1980 to 1996 [Review]. Ann Intern Med 1998;128:922-30.
118. Paddock CD, Greer PW, Ferebee T, et al. Hidden mortality attributable to Rocky Mountain spotted fever: immunohistochemical detection of fatal, serologically unconfirmed cases. J Infect Dis 1999;179:1469-76.
119. Thorner AR, Walker DH, Petri WA, Jr. Rocky Mountain spotted fever [Review]. Clin Infect Dis 1998;27:1353-9.
120. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995;52:405-13.
121. Schluter WW, Reef SE, Redd SC, Dykewicz CA, Changing epidemiology of congenital rubella syndrome in the United States. J Infect Dis 1998;178:636-41.
122. CDC. Rubella outbreak - Westchester County, New York, 1997-98. MMWR 1999;48:560-3.
123. CDC. Rubella and congenital rubella syndrome - United States, 1994-1997. MMWR 1997;46:350-4.
124. CDC. Rubella and congenital rubella syndrome - United States, January 1, 1991-May 7, 1994. MMWR 1994;43:391,397-401.
125. CDC. Rubella among crew members of commercial cruise ships - Florida, 1997. MMWR 1998;46:1247-50.
126. Van Beneden CA, Keene WE, Strang RA, et al. Multinational outbreak of Salmonella enterics serotype Newport infections due to contaminated alfalfa sprouts. JAMA 1999;281:158-62.
127. Mahon BE, Slutsker L, Hutwagner L, et al. Consequences in Georgia of a nationwide outbreak of Salmonella infections: what you don't know might hurt you. Am J Public Health 1999;89:31-5.
128. Glynn MK, Bopp C, Dewitt WK, Dabney P, Mokhtar M, Angulo FJ. Emergence of multidrug-resistant Salmonella enterica serotype Typhimurium DT 104 infections in the United States. N Engl J Med 1998;338:1333-8.
129. CDC. Multistate outbreak of Salmonella serotype Agona infections linked to toasted oats cereal - United States, April-May, 1998. MMWR 1998;47:462-4.
130. Sobel J, Cameron DN, Ismail J, et al. A prolonged outbreak of Shigella sonnei infections in traditionally observant Jewish communities in North America caused by a molecularly distinct bacterial subtype. J Infect Dis 1998;177:1405-8.
131. Mohle-Boetani JC, Stapleton M, Finger R, et al. Communitywide shigellosis: control of an out-break and risk factors in child day-care centers. Am J Public Health 1995;85:812-6.
132. Ries AA, Wells JG, Olivola D, et al. Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention. J Infect Dis 1994;169:1035-41.
133. Lee LA, Shapiro CN, Hargrett-Bean N, Tauxe RV. Hyperendemic shigellosis in the United States: a review of surveillance data for 1967-1988. J Infect Dis 1991;164:894-900.
134. CDC. Noscomial group A streptococcal infections associated with asymptomatic health-care workers - Maryland and California, 1997. MMWR 1999;48:163-6.
135. The Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive group A streptococcal disease among household contacts of case-patients: is prophylaxis warranted? JAMA 1998;279:1206-10.
136. Davies HD, McGeer A, Schwartz B, et al. A prospective, population-based study of invasive group A streptococcal infections, including toxic shock syndrome and the risk of secondary infections. N Engl J Med 1996;335:547-54.
137. Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993;269:390-1.
138. Schuchat A. Group B streptococcus [Review]. Lancet 1999;353:51-6.
139. CDC. Adoption of hospital policies for prevention of perinatal group B streptococcal disease - United States, 1997. MMWR 1998;47:665-70.
140. Factor SH, Levine OS, Nassar A, et al. Impact of a risk-based prevention policy on neonatal group B streptococcal disease. Am J Obstet Gynecol 1998;179:1568-71.
141. CDC. Decreasing incidence of perinatal group B streptococcal disease - United States, 1993-1995. MMWR 1997;46:473-7.
142. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group [published erratum appears in Pediatr Infect Dis J 1999;18(4):341]. Pediatr Infect Dis J 1999;18:1-9.
143. Dowell SF. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatrics 1998;101(suppl):S163- S184.
144. CDC. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR 1996;45(No. RR-1).
145. Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996;174:986-93.
146. Southwick KL, Guidry HM, Weldon MM, Mertz KJ, Berman SM, Levine WC. An epidemic of congenital syphilis in Jefferson County, Texas, 1994-1995: inadequate prenatal syphilis testing after an outbreak in adults. Am J Public Health 1999;89:557-60.
147. Coles BF, Hipp SS, Silberstein GS, Chen JH. Congenital syphilis surveillance in upstate New York, 1989-1992: implications for prevention and clinical management. J Infect Dis 1995;171:732-5.
148. CDC. Congenital syphilis - United States, 1998. MMWR 1999;48;757-61.
149. CDC. Guidelines for the prevention and control of congenital syphilis. MMWR 1988;37(No. S-1).
150. Williams LA, Klausner JD, Whittington WL, Handsfield HH, Celum C, Holmes KK. Elimination and reintroduction of primary and secondary syphilis. Am J Public Health 1999;89:1093-7.
151. CDC. Primary and secondary syphilis - United States, 1998. MMWR 1999;48:873-8.
152. St. Louis ME, Wasserheit JN. Elimination of syphilis in the United States. Science 1998;281:353-4.
153. Nakashima AK, Rolfs RT, Flock ML, Kilmarx P, Greenspan JR. Epidemiology of syphilis in the United States, 1941-1993. Sex Transm Dis 1996;23:16-23.
154. Bardenheier B, Prevots R, Khetsuriani N, Wharton M. Tetanus surveillance-United States, 1995-1997. In: CDC surveillance summaries, July 3,1998. MMWR 1998;47(No. SS-2):1-13.
155. CDC. Neonatal tetanus - Montana, 1998. MMWR 1998;47:928-30.
156. CDC. Tetanus among injecting-drug users - California, 1997. MMWR 1998;47:149-51.
157. Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutler RW, Virella G. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995;332:761-6.
158. Hajjeh RA, Reingold R, Weil A, Shutt K, Schuchat A, Perkins BA. Toxic shock syndrome in the United States: surveillance update, 1979-1996. Emerg Infect Dis 1999;5. Available on the Internet at 〈http://www.cdc.gov/ncidod/ eid/vol5no6/hajjeh.htm〉.
159. Schuchat A, Broome CV. Toxic shock syndrome and tampons. Epidemiol Rev 1991;13:99-112.
160. CDC. Reduced incidence of menstrual toxic shock syndrome - United States, 1980-1990. MMWR 1990;39:421-3.
161. Gaventa S, Reingold AL, Hightower AW, et al. Active surveillance for toxic shock syndrome in the United States, 1986. Reviews of Infectious Disease 1989;11(suppl):S28-S34.
162. Moorhead A, Grunenwald PE, Dietz VJ, Schantz PM. Trichinellosis in the United States, 1991-1996: declining but not gone. Am J Trop Med Hyg 1999;60:66-9.
163. CDC. Outbreak of trichinellosis associated with eating cougar jerky - Idaho, 1995. MMWR 1996;45:205-6.
164. McAuley JB, Michelson MK, Schantz PM. Trichinosis surveillance, United States, 1987-1990. In: CDC surveillance summaries, December 1991. MMWR 1991;40(No. SS-3):35-42.
165. CDC. Recommendations for counting reported tuberculosis cases. In: Reported tuberculosis in the United States, 1996. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1997:61-8.
166. American Thoracic Society, CDC. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-74.
167. Mermin J, Villar R, Carpenter J, et al. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. J Infect Dis 1999;179:1416-22.
168. Mermin JH, Townes JM, Gerber M, Dolan N, Mintz ED, Tauxe RV. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998;158:633-8.
169. CDC. Typhoid immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994;43(No. RR-14).
170. Woodruff BA, Pavia AT, Blake PA. A new look at typhoid vaccination: information for the practicing physician. JAMA 1991,-265:756-9.
171. CDC. Evaluation of varicella reporting to the National Notifiable Disease Surveillance System - United States, 1972-1997. MMWR 1999;48:55-8.
172. CDC. Prevention of varicella. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999:48(No. RR-6).
173. CDC. Varicella-related deaths among children - United States, 1997. MMWR 1998;47:365-8.
174. CDC. Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(No. RR-11).